Trials / Completed
CompletedNCT00353678
Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)
Direct Factor Xa Inhibitor YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement.---A Double Blind, Parallel, Dose-finding Study in Comparison With Open Label Enoxaparin
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,141 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find the best possible (optimal) dose (effect versus adverse events) of YM150 to prevent the risk of blood clot formation after scheduled hip replacement surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YM150 |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2007-08-01
- Completion
- 2007-08-01
- First posted
- 2006-07-19
- Last updated
- 2013-03-21
Locations
79 sites across 17 countries: Austria, Bosnia and Herzegovina, Czechia, Denmark, Finland, Germany, Greece, Italy, Latvia, Lithuania, Norway, Poland, Russia, Serbia, Slovakia, Spain, Sweden
Source: ClinicalTrials.gov record NCT00353678. Inclusion in this directory is not an endorsement.